Cherrie K. Donawho
AbbVie (United States)(US)
Publications by Year
Research Areas
Protein Degradation and Inhibitors, PARP inhibition in cancer therapy, Multiple Myeloma Research and Treatments, CAR-T cell therapy research, DNA Repair Mechanisms
Most-Cited Works
- → ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models(2007)764 cited
- → Discovery of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the Treatment of Cancer(2008)266 cited
- → Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors(2015)262 cited
- → PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow(2018)251 cited
- → Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor(2011)175 cited
- → Molecular Regulation of UVB-Induced Cutaneous Angiogenesis(1998)142 cited
- → ABT-888 Confers Broad In vivo Activity in Combination with Temozolomide in Diverse Tumors(2009)139 cited
- → Venetoclax Increases Intratumoral Effector T Cells and Antitumor Efficacy in Combination with Immune Checkpoint Blockade(2020)125 cited
- → Effect of Sunscreens on UV Radiation-Induced Enhancement of Melanoma Growth in Mice(1994)124 cited
- → Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies(2017)118 cited